Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081.

J Immunother Cancer · 2025 · PMC12265819 · PMID 40664454

Europe PMC DOI

hedged sentence

0.0042

closest p · 0.1× alpha

0.0042

boldest claim

The sentences

not quite statistically significantp=0.0042actually significant

In the nivolumab/ipilimumab arm, PFS was numerically higher in the PD-L1≥1% group (median 15.1 months vs NR, p=0.0518) though not quite statistically significant, and the OS also favored the PD-L1≥1% group (median 26.1 months vs NR, p=0.0042).

also in 55 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.